XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisition Of Ascyrus (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 02, 2020
Mar. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]      
Current portion of contingent consideration   $ 16,800 $ 16,430
Noncurrent portion of contingent consideration   44,100 43,500
Goodwill   253,950 260,061
Cash distribution from escrow   777  
Following FDA Approval For AMDS [Member]      
Business Acquisition [Line Items]      
Aggregate amount of consideration transferred   120,000  
Ascyrus Medical LLC [Member]      
Business Acquisition [Line Items]      
Aggregate amount of consideration transferred $ 82,400    
Total consideration   137,766  
Equity ownership percent 100.00%    
Cash consideration $ 62,400    
Common shares issued 991,800    
Common stock value issued in business combination $ 20,000    
Period for weighted average closing price 10 days    
Current portion of contingent consideration   16,800 16,400
Noncurrent portion of contingent consideration   44,100 $ 43,500
Goodwill   62,515  
Fair value of combined purchase consideration $ 137,800    
Contingent consideration, fair value adjustment   970  
Amount of goodwill deducted for tax purposes   61,200  
Fair value of total consideration   $ 137,766  
Ascyrus Medical LLC [Member] | FDA Approval IDE for AMDS [Member]      
Business Acquisition [Line Items]      
Cash consideration 60,000    
Common stock value issued in business combination 20,000    
Ascyrus Medical LLC [Member] | FDA Approval IDE for AMDS [Member] | Maximum [Member]      
Business Acquisition [Line Items]      
Aggregate amount of consideration transferred 200,000    
Ascyrus Medical LLC [Member] | FDA Approves Premarket Approval [Member]      
Business Acquisition [Line Items]      
Cash consideration 10,000    
Common stock value issued in business combination 10,000    
Ascyrus Medical LLC [Member] | AMDS Obtained In Japan [Member]      
Business Acquisition [Line Items]      
Cash consideration 25,000    
Ascyrus Medical LLC [Member] | AMDS Obtained In China [Member]      
Business Acquisition [Line Items]      
Cash consideration 10,000    
Ascyrus Medical LLC [Member] | If Japan Or China Obtains Approval [Member]      
Business Acquisition [Line Items]      
Cash consideration 10,000    
Ascyrus Medical LLC [Member] | Additional Potential Cash Payment If Japan Or China Obtains Approval [Member]      
Business Acquisition [Line Items]      
Cash consideration 55,000    
Ascyrus Medical LLC [Member] | Additional Potential Cash Payment If Japan Or China Obtains Approval [Member] | Minimum [Member]      
Business Acquisition [Line Items]      
Cash consideration 65,000    
Ascyrus Medical LLC [Member] | Additional Potential Cash Payment If Japan Or China Obtains Approval [Member] | Maximum [Member]      
Business Acquisition [Line Items]      
Cash consideration $ 75,000    
Ascyrus Medical LLC [Member] | Following FDA Approval For AMDS [Member]      
Business Acquisition [Line Items]      
Period of required contingent consideration 3 years